Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Alizé Pharma

March 2, 2015
Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome. More

September 10, 2014
Alize Pharma raises EUR 5 million (USD 6.6 million) from Bpifrance/InnoBio and its existing share...
The proceeds will finance the clinical development program of AZP­531 (an unacylated ghrelin analog) in Prader-Willi syndrome and type 2 diabetes. More

December 3, 2009
Alizé Pharma reveals promising data on Asparec program for second-line ALL therapy
Metabolic disease and cancer specialist will present preclinical data on therapy for acute lymphoblastic leukemia (ALL) at the American Society of Hematology, New Orleans, Louisiana, December 6, 2009. More

Data


27,633
Tech investments
From our Online Data Service
17,827
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology
Dec 3€21.0MBusiness applications
Dec 2€7.0MDigital signal processing
Dec 2€7.4MBiotechnology
Nov 30€3.7MConsumer electronics
Nov 12€20.0MAgriculture related

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.